Olodanrigan

Potent (IC50 = 39.5 nM) and selective (>10,000-fold selectivity AT2R/AT1R) antagonist of the angiotensin II type 2 receptor.1 It produced dose-dependent relief of hindpaw sensitivity in a rat model of neuropathic pain1 and showed efficacy in a human trial against postherpetic neuralgia2. Olodanrigan prevented paclitaxel-associated acute pain syndrome in mice.3 It blocked visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome.4 It was also able to inhibit proliferation of AT2R-expressing glioblastoma spheroids and blocked their invasiveness and angiogenic capability.5